Recap: Amarin Q2 Earnings

 

Shares of Amarin Corp AMRN rose 0.7% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 100.00% over the past year to $0.02, which beat the estimate of ($0.03).

Revenue of $154,488,000 higher by 14.17% from the same period last year, which beat the estimate of $153,760,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Amarin Corp hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 05, 2021

Time: 07:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2037/42077

Technicals

Company's 52-week high was at $9.25

Company's 52-week low was at $3.36

Price action over last quarter: down 12.18%

Company Description

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!